IMMUNOSUPPRESSION WITH AZATHIOPRINE AND PREDNISONE IN RECENT-ONSET INSULIN-DEPENDENT DIABETES-MELLITUS
IMMUNOSUPPRESSION WITH AZATHIOPRINE AND PREDNISONE IN RECENT-ONSET INSULIN-DEPENDENT DIABETES-MELLITUS
复制标题
DOI：
10.1056/nejm198809083191002
复制
发表时间：
1988-09-08
影响因子：
158.5
通讯作者：
JOHNSON, S
中科院分区：
文献类型：
--
作者：
SILVERSTEIN, J;MACLAREN, N;JOHNSON, S
We randomly assigned 46 patients (mean age, 11.7 years; range, 4.5 to 32.8) with newly diagnosed insulin-dependent diabetes mellitus within two weeks of beginning insulin to receive either corticosteroids for 10 weeks plus daily azathioprine for one year or non immunosuppressive therapy. Half the 20 immunosuppressed patients completing the one-year trial had satisfactory metabolic outcomes (hemoglobin A1c < 6.8 percent; stimulated peak C peptide > 0.5 nmol per liter; insulin dose < 0.4 U per kilogram of body weight per day) as compared with only 15 percent of the controls. Three of 20 immunosuppressed patients, but no controls, were insulin independent at one year. Two of these continue to receive azathioprine without insulin after more than 27 months of follow-up. The response to immunosuppression correlated with older age, better initial metabolic status, and lymphopenia (< 1800 lymphocytes per cubic millimeter) resulting from immunosuppression. The side effects of azathioprine included vomiting in one patient and mild hair loss in several others. Prednisone used resulted in a transient cushingoid appearance, weight gain, and hyperglycemia. The growth rate remained normal in all patients. We conclude that early immunosuppression with shortterm use of corticosteroids plus daily azathioprine can improve metabolic control in some patients with insulin-dependent diabetes mellitus, but results from this unblinded study are preliminary and require further confirmation and long-term follow-up.
